Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Vaxcyte stock | $22.71

Learn how to easily invest in Vaxcyte stock.

Vaxcyte Inc is a biotechnology business based in the US. Vaxcyte shares (PCVX) are listed on the NASDAQ and all prices are listed in US Dollars. Vaxcyte employs 58 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Vaxcyte

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PCVX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Vaxcyte stock price (NASDAQ: PCVX)

Use our graph to track the performance of PCVX stocks over time.

Vaxcyte shares at a glance

Information last updated 2021-10-17.
Latest market close$22.71
52-week range$15.51 - $46.84
50-day moving average $25.58
200-day moving average $22.54
Wall St. target price$50.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.69

Buy Vaxcyte shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Vaxcyte stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Vaxcyte price performance over time

Historical closes compared with the close of $22.71 from 2021-10-22

1 week (2021-10-15) -6.96%
1 month (2021-09-23) -13.25%
3 months (2021-07-23) 0.84%
6 months (2021-04-23) 19.72%
1 year (2020-10-23) -47.85%
2 years (2019-10-19) N/A
3 years (2018-10-19) N/A
5 years (2016-10-19) N/A

Vaxcyte financials

Gross profit TTM $0
Return on assets TTM -14.15%
Return on equity TTM -24.75%
Profit margin 0%
Book value $6.10
Market capitalisation $1.3 billion

TTM: trailing 12 months

Shorting Vaxcyte shares

There are currently 1.4 million Vaxcyte shares held short by investors – that's known as Vaxcyte's "short interest". This figure is 20.3% down from 1.8 million last month.

There are a few different ways that this level of interest in shorting Vaxcyte shares can be evaluated.

Vaxcyte's "short interest ratio" (SIR)

Vaxcyte's "short interest ratio" (SIR) is the quantity of Vaxcyte shares currently shorted divided by the average quantity of Vaxcyte shares traded daily (recently around 192527.33423545). Vaxcyte's SIR currently stands at 7.39. In other words for every 100,000 Vaxcyte shares traded daily on the market, roughly 7390 shares are currently held short.

However Vaxcyte's short interest can also be evaluated against the total number of Vaxcyte shares, or, against the total number of tradable Vaxcyte shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vaxcyte's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Vaxcyte shares in existence, roughly 30 shares are currently held short) or 0.0443% of the tradable shares (for every 100,000 tradable Vaxcyte shares, roughly 44 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Vaxcyte.

Find out more about how you can short Vaxcyte stock.

Vaxcyte share dividends

We're not expecting Vaxcyte to pay a dividend over the next 12 months.

Vaxcyte overview

Vaxcyte, Inc. , a preclinical-stage biotechnology vaccine company, develops novel vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting Porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020.

Frequently asked questions

What percentage of Vaxcyte is owned by insiders or institutions?
Currently 7.753% of Vaxcyte shares are held by insiders and 89.621% by institutions.
How many people work for Vaxcyte?
Latest data suggests 58 work at Vaxcyte.
When does the fiscal year end for Vaxcyte?
Vaxcyte's fiscal year ends in December.
Where is Vaxcyte based?
Vaxcyte's address is: 353 Hatch Drive, Foster City, CA, United States, 94404
What is Vaxcyte's ISIN number?
Vaxcyte's international securities identification number is: US92243G1085

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site